ArQule, Inc, a biopharmaceutical company, researches and develops therapeutics for the treatment of cancer and rare diseases in the United States. The company's pipeline includes ARQ 531, an orally bioavailable, potent and reversible dual inhibitor of wild type and C481S-mutant Bruton's tyrosine kinase that is in Phase I trial for patients with B-cell malignancies refractory to other therapeutic options; and miransertib (ARQ 092), a potent and selective inhibitor of the protein kinase B (AKT), a serine/threonine kinase, which is in Phase Ib in combination with the hormonal therapy and anastrozole in patients with advanced endometrial cancer.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone781-994-0300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$25.76 million
Profitability
Miscellaneous
Employees36
Next Earnings Date10/30/2019 (Estimated)
OptionableOptionable
ArQule (NASDAQ:ARQL) Frequently Asked Questions
What is ArQule's stock symbol?
ArQule trades on the NASDAQ under the ticker symbol "ARQL."
How were ArQule's earnings last quarter?
ArQule, Inc. (NASDAQ:ARQL) released its quarterly earnings results on Wednesday, August, 7th. The biotechnology company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.09) by $0.01. The biotechnology company earned $0.28 million during the quarter, compared to the consensus estimate of $1.43 million. ArQule had a negative return on equity of 33.45% and a negative net margin of 349.34%. During the same quarter in the previous year, the business earned $0.05 EPS. View ArQule's Earnings History.
When is ArQule's next earnings date?
What guidance has ArQule issued on next quarter's earnings?
ArQule issued an update on its FY 2019 earnings guidance on Wednesday, August, 7th. The company provided EPS guidance of $-0.37--0.35 for the period, compared to the Thomson Reuters consensus estimate of $-0.38. The company issued revenue guidance of $3-5 million, compared to the consensus revenue estimate of $4.25 million.
What price target have analysts set for ARQL?
5 Wall Street analysts have issued 1-year price targets for ArQule's shares. Their predictions range from $11.00 to $13.00. On average, they anticipate ArQule's stock price to reach $12.20 in the next year. This suggests a possible upside of 36.2% from the stock's current price. View Analyst Price Targets for ArQule.
What is the consensus analysts' recommendation for ArQule?
5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ArQule in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ArQule.
Has ArQule been receiving favorable news coverage?
Media stories about ARQL stock have trended negative recently, according to InfoTrie. The research group identifies positive and negative media coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. ArQule earned a media sentiment score of -2.3 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View News Stories for ArQule.
Who are some of ArQule's key competitors?
Some companies that are related to ArQule include Blueprint Medicines (BPMC), FibroGen (FGEN), Allakos (ALLK), Mirati Therapeutics (MRTX), United Therapeutics (UTHR), Ultragenyx Pharmaceutical (RARE), Alkermes (ALKS), BridgeBio Pharma (BBIO), Nektar Therapeutics (NKTR), Evotec (EVTCY), Taro Pharmaceutical Industries (TARO), Global Blood Therapeutics (GBT), Arrowhead Pharmaceuticals (ARWR), HUTCHISON CHINA/S (HCM) and Arena Pharmaceuticals (ARNA).
What other stocks do shareholders of ArQule own?
Who are ArQule's key executives?
ArQule's management team includes the folowing people:
- Mr. Paolo Pucci, CEO & Director (Age 58)
- Mr. Peter S. Lawrence J.D., Pres, COO, Gen. Counsel & Sec. (Age 56)
- Dr. Brian Schwartz, Chief Medical Officer & Sr. VP (Age 57)
- Mr. Robert J. Weiskopf, CFO, Sr. VP, Principal Accounting Officer & Treasurer (Age 68)
- Dr. Marc Schegerin M.D., CFO, Head of Strategy & Treasurer
Who are ArQule's major shareholders?
ArQule's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (7.47%), Vanguard Group Inc. (4.69%), Eagle Asset Management Inc. (2.54%), Candriam Luxembourg S.C.A. (2.51%), Point72 Asset Management L.P. (2.26%) and Carillon Tower Advisers Inc. (2.19%). Company insiders that own ArQule stock include Paolo Pucci, Patrick J Zenner, Ran Nussbaum, Ronald M Lindsay and Value Fund L P Biotechnology. View Institutional Ownership Trends for ArQule.
Which institutional investors are selling ArQule stock?
ARQL stock was sold by a variety of institutional investors in the last quarter, including Eversept Partners LP, Sofinnova Investments Inc., Alps Advisors Inc., Handelsbanken Fonder AB, AQR Capital Management LLC, GSA Capital Partners LLP, Morgan Stanley and Moloney Securities Asset Management LLC. View Insider Buying and Selling for ArQule.
Which institutional investors are buying ArQule stock?
ARQL stock was bought by a variety of institutional investors in the last quarter, including Eagle Asset Management Inc., Point72 Asset Management L.P., Carillon Tower Advisers Inc., Emerald Advisers LLC, Marshall Wace North America L.P., Emerald Mutual Fund Advisers Trust, Candriam Luxembourg S.C.A. and Nuveen Asset Management LLC. Company insiders that have bought ArQule stock in the last two years include Paolo Pucci, Patrick J Zenner, Ran Nussbaum and Ronald M Lindsay. View Insider Buying and Selling for ArQule.
How do I buy shares of ArQule?
Shares of ARQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ArQule's stock price today?
One share of ARQL stock can currently be purchased for approximately $8.96.
How big of a company is ArQule?
ArQule has a market capitalization of $1.08 billion and generates $25.76 million in revenue each year. The biotechnology company earns $-15,480,000.00 in net income (profit) each year or ($0.16) on an earnings per share basis. ArQule employs 36 workers across the globe.View Additional Information About ArQule.
What is ArQule's official website?
How can I contact ArQule?
ArQule's mailing address is ONE WALL STREET, BURLINGTON MA, 01803. The biotechnology company can be reached via phone at 781-994-0300 or via email at [email protected]
MarketBeat Community Rating for ArQule (NASDAQ ARQL)
MarketBeat's community ratings are surveys of what our community members think about ArQule and other stocks. Vote "Outperform" if you believe ARQL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARQL will underperform the S&P 500 over the long term. You may vote once every thirty days.
